These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32141356)

  • 1. Treatment options after first-line immunotherapy in metastatic NSCLC.
    Santos ES
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):221-228. PubMed ID: 32141356
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
    Cetin B; Bilgetekin İ; Ozet A
    Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 7. Current status of immune checkpoint inhibition in early-stage NSCLC.
    Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D
    Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
    Zouein J; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
    Gomes F; Wong M; Battisti NML; Kordbacheh T; Kiderlen M; Greystoke A; Luciani A
    Br J Cancer; 2020 Sep; 123(6):874-884. PubMed ID: 32694695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
    Pabani A; Butts CA
    Curr Oncol; 2018 Jun; 25(Suppl 1):S94-S102. PubMed ID: 29910652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
    Wang S; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles of Immunotherapy in Non-Small Cell Lung Cancer.
    Hsu ML; Naidoo J
    Thorac Surg Clin; 2020 May; 30(2):187-198. PubMed ID: 32327177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Lingering Questions in Immunotherapy.
    Wright K
    Oncology (Williston Park); 2020 Mar; 34(3):. PubMed ID: 32212135
    [No Abstract]   [Full Text] [Related]  

  • 16. [Immunotherapy in non-small cell lung cancer patients: back to the future.].
    Roberto M; Botticelli A; Cecere F; Cognetti F; Giusti R; Gelibter A; Lugini A; Nelli F; Nuti M; Santini D; Marchetti P
    Recenti Prog Med; 2019 Dec; 110(12):587-593. PubMed ID: 31909761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inoperable Early-Stage Non-Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy.
    Daly ME
    J Clin Oncol; 2022 Feb; 40(6):539-545. PubMed ID: 34985921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
    Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F
    Expert Opin Biol Ther; 2016 Dec; 16(12):1479-1489. PubMed ID: 27650132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer.
    Hallqvist A; Rohlin A; Raghavan S
    Scand J Immunol; 2020 Dec; 92(6):e12980. PubMed ID: 33015859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in immunotherapy for non-small cell lung cancer.
    Reckamp KL
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):847-53. PubMed ID: 27058851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.